Bharat Parenterals working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY23Mar 2023FY22Mar 2022
77.79×55.69×
155.56×126.37×
93.53×60.46×
139.82×121.60×
0.83×0.97×
−0.48×—
−0.54×—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

BPLPHARMA₹1,912.60

Bharat Parenterals Limited

· Pharma & Health
₹ CrorePeersJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOCMcap ₹1,105 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
Inventory Days (DIO)55.6977.79
Receivable Days (DSO)126.37155.56
Payable Days (DPO)60.4693.53
Cash Conversion Cycle (days)121.60139.82
Asset Turnover0.970.83
Cash Conversion (CFO/Net Income)—-0.48
CFO/EBITDA—-0.54
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY23 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.